Synaptogenix, Inc.
Synaptogenix, Inc. (SNPX) Stock Overview
Explore Synaptogenix, Inc.’s financial performance, market position, analyst ratings, and future outlook.
SNPX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Synaptogenix, Inc. (SNPX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $1.27.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.67 and a market capitalization of 8.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Alan J. Tuchman MBA(FAAN)
4
1185 Avenue of the Americas, New York City, NY
2020